There is limited experience with use of third line regimen in sub-Saharan Africa. It is expected that about 10% of those on 1st line treatment will fail and to be switched to 2nd line. Another 10% of those on 2nd line are also expected to fail and be switched to 3rd line. Recommendation for 3rd line in the guidelines is to include new drugs with minimal risk of cross resistance to previously used regimens such as Integrase Inhibitors and second-generation NNRTIs and PIs. We present three cases on third-line regimen on boosted Darunavir, Etravirine and Raltegravir. 66.7% viral suppression was achieved after four years of access to the medication. The third line regimen was well tolerated by the three cases and there was no report of serious adverse drug reaction. Adherence was also good in all cases. Third line regimen is effective but there is need to secure access. The cases reported had to interrupt treatment because access to free third-line ART was terminated by implementing partners. The Nigerian government is encouraged to take up the responsibility to provide third line regimen.
Herbertson EC, Gbajabiamila TA, Ekama SO, Idigbe IE
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : July 20, 2019